Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib

NCT04334044 is registered in ClinicalTrials.gov with Grupo Cooperativo de Hemopatías Malignas as lead sponsor.

NCT NCT04334044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04334044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib
Lead sponsor
Grupo Cooperativo de Hemopatías Malignas
Phase
Phase 1/2
Overall status
Completed
Start date
September 1, 2020
Completion date
April 30, 2021
Enrollment
77 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, severe acute respiratory syndrome coronavirus 2